Mirum Q1 2023 LIVMARLI sales $29.1M, up 167% YoY; closed $316M convertible note

Mirum Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.80 revenue$31,598,000

Net product sales for LIVMARLI $29.1M in Q1 2023 vs $10.9M in Q1 2022, a 167% increase.
Total revenue $31.6M; operating expenses $58.7M; cash $232.1M as of March 31, 2023.
FDA approved label expansion for LIVMARLI to include infants 3 months+ in Alagille syndrome.
sNDA for LIVMARLI in PFIC accepted with PDUFA date December 13, 2023.
Closed $316.3M upsized convertible notes offering at 4.00% due 2029; repurchased 9.75% royalty obligation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. reported first quarter 2023 results: revenue $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million.

Period: first quarter 2023
Revenue: $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million
Result: reported results

Exact text from the filing

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-000741

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.